Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330530 | 0.85 | ALDH1A1 (0.54) | ALDH1A1GAANPSR1KDM4ETSHR | |
| SCHEMBL23330486 | 0.82 | MAPT (0.46) | ALDH1A1GAANPSR1KDM4ETSHR | |
| SCHEMBL23331259 | 0.76 | MEN1 (0.40) | ALDH1A1GAANPSR1KDM4ETSHR | |
| SCHEMBL23331078 | 0.75 | HDAC1 (0.49) | KMT2A | |
| SCHEMBL23331245 | 0.74 | P2RX7 (0.40) | GAAPOLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23330666 | 0.73 | ABL1 (0.39) | ALDH1A1KDM4EPOLBHSD17B10KMT2A | |
| SCHEMBL23330675 | 0.73 | ALDH1A1 (0.44) | ALDH1A1GAANPSR1KDM4ETSHR | |
| SCHEMBL23330832 | 0.72 | NFKB1 (0.34) | ALDH1A1GAA | |
| SCHEMBL23331251 | 0.71 | PTK2 (0.39) | KDM4EPOLBL3MBTL1HSD17B10 | |
| SCHEMBL23330835 | 0.71 | BRAF (0.36) | POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | ALDH1A1 650/4885GAA 982/4885NPSR1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.